BeStock  
Stocks › Biotechnology › SYRE

Spyre Therapeutics SYRE

US equityMarket cap rank #1512Biotechnology
$93.47 −$4.16 (-4.26%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $93.47 0.00%
Open$95.93
Prev close$97.63
Day range$93.22 – $99.56
Volume805.4K
Market cap$8.88B
P/E (TTM)–
Dividend yield–

SYRE Stock News

Headlines matching Spyre Therapeutics or the SYRE ticker, most recent first.

  • Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126 PositiveMarket news · 9 Sep 2026 · Direct mention
  • Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 PositiveMarket news · 9 Sep 2026 · Direct mention
  • LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116Market news · 9 Sep 2026 · Direct mention
  • Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123Market news · 9 Sep 2026 · Direct mention
  • JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121Market news · 28 Sep 2026 · Direct mention
  • LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 PositiveMarket news · 8 Aug 2026 · Direct mention
  • Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130 PositiveMarket news · 6 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130Market news · 27 Aug 2026 · Direct mention
  • Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130Market news · 27 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127Market news · 26 Aug 2026 · Direct mention
  • LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129Market news · 15 Aug 2026 · Direct mention
  • Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123Market news · 14 Aug 2026 · Direct mention
  • JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140 PositiveMarket news · 13 Aug 2026 · Direct mention
  • BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132 PositiveMarket news · 11 Aug 2026 · Direct mention
  • LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129 PositiveMarket news · 11 Aug 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on SYRE.

Sign in to join the discussion.

Scroll to Top